Subscribe
olm26250-istockphoto-com-patent-2-1-
olm26250 / iStockphoto.com
28 March 2019Big Pharma

Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers

The UK Supreme Court’s  decision in Actavis v Eli Lilly  confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB